Talis Biomedical Income After Taxes 2020-2024 | TLIS

Talis Biomedical income after taxes from 2020 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.

Talis Biomedical Income After Taxes 2020-2024 | TLIS

Talis Biomedical income after taxes from 2020 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$140.4B
Bristol Myers Squibb (BMY)$114.2B
Gilead Sciences (GILD)$113.5B
Vertex Pharmaceuticals (VRTX)$102.1B
CSL (CSLLY)$83.7B
Regeneron Pharmaceuticals (REGN)$77.8B
GSK (GSK)$69.3B
Argenex SE (ARGX)$37.8B
Alnylam Pharmaceuticals (ALNY)$30.8B
BioNTech SE (BNTX)$26.5B
Biogen (BIIB)$21.5B
Illumina (ILMN)$21.3B
BeiGene (BGNE)$17B
Moderna (MRNA)$15.2B
Genmab (GMAB)$13.3B
Incyte (INCY)$12.9B
Insmed (INSM)$12.4B
BioMarin Pharmaceutical (BMRN)$12.4B
Sarepta Therapeutics (SRPT)$11.4B
Bio-Techne Corp (TECH)$11.3B
Vaxcyte (PCVX)$10.7B
Exact Sciences (EXAS)$10.4B
Swedish Orphan Biovitrum (BIOVF)$10.2B
QIAGEN (QGEN)$10.1B
Exelixis (EXEL)$9.6B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$8.9B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$8.4B
Repligen (RGEN)$8.2B